Q-omics provides the consensus-scored FAM122A profile across patient tissues and cancer cell-line models. FAM122A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM122A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FAM122A RNA expression shows 19,902 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where FAM122A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM122A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM122A survival associations across molecular data types. FAM122A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM122A RNA expression–survival associations across cancer types. High FAM122A expression shows unfavorable associations in UCS, but favorable associations in KIRC, UCEC, PRAD, BRCA and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM122A RNA expression.
This table summarizes FAM122A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM122A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM122A shows lower tumor expression in THCA, KIRC, UCEC, BLCA, LUAD and BRCA. The THCA box plot shows higher FAM122A RNA expression in normal versus tumor tissue (log2 FC = −1.048, t-test p < 0.001).
This table shows molecular features associated with FAM122A in patient tissues and cancer cell lines. In patient samples, FAM122A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM122A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
